Open Access

Polycomb group expression signatures in the malignant progression of gliomas

  • Authors:
    • Qi Hu
    • Weining Wu
    • Ailiang Zeng
    • Tianfu Yu
    • Feng Shen
    • Er Nie
    • Yingyi Wang
    • Ning Liu
    • Junxia Zhang
    • Yongping You
  • View Affiliations

  • Published online on: February 20, 2017     https://doi.org/10.3892/ol.2017.5753
  • Pages: 2583-2590
  • Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Polycomb group (PcG) proteins form at least two key complexes, namely polycomb repressive complex 1 and polycomb repressive complex 2. These complexes are involved in the progression of various cancers. Systematic research has not been conducted on the aberrant expression of PcG members in gliomas. Using the Chinese Glioma Genome Atlas data set, PcG expression patterns between normal brain tissues and glioma samples were analyzed, and a PcG‑based classifier was then developed using BRB Cox regression and risk‑score model. These results were validated in an independent GSE16011 set. A total of six PcGs [chromobox protein homolog (CBX) 6, CBX7, PHD finger protein 1, enhancer of zeste homolog 2 (EZH2), DNA (cytosine‑5‑)‑methyltransferase 3β (DNMT3B) and polyhomeotic‑like protein 2] were identified to be associated with glioma grade. Survival analysis then revealed a five‑PcG gene signature one protective gene (enhancer of zeste homolog 1) and four risky genes (EZH2, PHD finger protein 19, DNMT3A and DNMT3B), which may identify patients with high risk of poor prognosis of glioma. Multivariate Cox analysis indicated that the five‑PcG signature was an independent prognostic biomarker. These findings indicated that a novel prognostic classifier, five‑PcG signature, served as an independent prognostic marker for patients with glioma.

Related Articles

Journal Cover

April-2017
Volume 13 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hu Q, Wu W, Zeng A, Yu T, Shen F, Nie E, Wang Y, Liu N, Zhang J, You Y, You Y, et al: Polycomb group expression signatures in the malignant progression of gliomas. Oncol Lett 13: 2583-2590, 2017
APA
Hu, Q., Wu, W., Zeng, A., Yu, T., Shen, F., Nie, E. ... You, Y. (2017). Polycomb group expression signatures in the malignant progression of gliomas. Oncology Letters, 13, 2583-2590. https://doi.org/10.3892/ol.2017.5753
MLA
Hu, Q., Wu, W., Zeng, A., Yu, T., Shen, F., Nie, E., Wang, Y., Liu, N., Zhang, J., You, Y."Polycomb group expression signatures in the malignant progression of gliomas". Oncology Letters 13.4 (2017): 2583-2590.
Chicago
Hu, Q., Wu, W., Zeng, A., Yu, T., Shen, F., Nie, E., Wang, Y., Liu, N., Zhang, J., You, Y."Polycomb group expression signatures in the malignant progression of gliomas". Oncology Letters 13, no. 4 (2017): 2583-2590. https://doi.org/10.3892/ol.2017.5753